Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 2/20 | 0.37 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.37 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611885 | 1.00 | DNM1 (0.44) | DNM1KCNH2TSHRTHRBKDM5A | |
| SCHEMBL15720779 | 1.00 | DNM1 (0.44) | DNM1KCNH2TSHRTHRBKDM5A | |
| SCHEMBL1461504 | 0.98 | DNM1 (0.40) | DNM1KCNH2TSHRKDM5APHF8 | |
| SCHEMBL9550792 | 0.95 | DNM1 (0.44) | DNM1KCNH2TSHRTHRBKDM5A | |
| SCHEMBL1462537 | 0.90 | CA12 (0.39) | KCNH2KDM5APHF8KDM4C | |
| SCHEMBL1461493 | 0.82 | CA12 (0.36) | TSHR | |
| SCHEMBL20658202 | 0.80 | KCNH2 (0.53) | DNM1KCNH2TSHRTHRB | |
| SCHEMBL17026408 | 0.80 | KCNH2 (0.53) | DNM1KCNH2TSHRTHRB | |
| SCHEMBL184235 | 0.79 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 | |
| SCHEMBL1461480 | 0.79 | DNM1 (0.48) | DNM1TSHRTHRBKDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-04 | — | — | US | disclosed |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-10-19 | — | — | US | disclosed |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-25 | — | — | US | disclosed |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| EP-2854815-B1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMA CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-20170196877-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-9669075-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-06 | — | — | US | disclosed |
| US-9636382-B2 | Drug for preventing and/or treating polycystic kidney disease | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-20140024619-A1 | Benzazepine Derivatives Useful as Vasopressin Antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-23 | — | — | US | disclosed |
| WO-2013180310-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-05 | — | — | WO | disclosed |
| EP-2374798-B1 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2374797-A1 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-12 | — | — | EP | disclosed |
| EP-2374798-A1 | Benzazepine derivatives useful as vasopressin antagonists | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110071084-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-03-24 | — | — | US | disclosed |
| EP-2170831-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009001968-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-12-31 | — | — | WO | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11147821-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | DNM1 2453/4885KCNH2 748/4885TSHR 317/4885 |
| US-11013746-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | DNM1 2453/4885KCNH2 748/4885TSHR 317/4885 |
| US-20190117666-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | DNM1 2453/4885KCNH2 748/4885TSHR 317/4885 |
| US-11957691-B2 | Drug for preventing and/or treating polycystic kidney disease | PKD1, PKD2, SSTR5 | DNM1 2453/4885KCNH2 748/4885TSHR 317/4885 |
| US-20110071084-A1 | BENZAZEPINE DERIVATIVES USEFUL AS VASOPRESSIN ANTAGONISTS | AVPR2, AVPR1B, AVPR1A | DNM1 2290/4885KCNH2 68/4885TSHR 503/4885 |
| US-20240216389-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | DNM1 2453/4885KCNH2 748/4885TSHR 317/4885 |
| US-20170239265-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | DNM1 2453/4885KCNH2 748/4885TSHR 317/4885 |
| US-20170196877-A1 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | PKD1, PKD2, SSTR5 | DNM1 2453/4885KCNH2 748/4885TSHR 317/4885 |
| US-20140024619-A1 | Benzazepine Derivatives Useful as Vasopressin Antagonists | AVPR2, AVPR1B, AVPR1A | DNM1 2315/4885KCNH2 71/4885TSHR 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.